Open Access

Regulatory effect of chemerin and therapeutic efficacy of chemerin‑9 in pancreatogenic diabetes mellitus

  • Authors:
    • Jianfeng Tu
    • Yue Yang
    • Jingzhu Zhang
    • Guotao Lu
    • Lu Ke
    • Zhihui Tong
    • Maimaitijiang Kasimu
    • Dejun Hu
    • Qiuran Xu
    • Weiqin Li
  • View Affiliations

  • Published online on: January 8, 2020     https://doi.org/10.3892/mmr.2020.10915
  • Pages: 981-988
  • Copyright: © Tu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemerin is a novel adipokine that regulates immune responses, adipocyte differentiation, and glucose metabolism. However, the role of chemerin in pancreatogenic diabetes mellitus (PDM) remains unknown. PDM is recognized as DM occurring secondary to chronic pancreatitis or pancreatic resection due to the loss of the loss of islet cell mass. The aim of the present study was to investigate the role of chemerin in PDM by collecting blooding samples from DM patients and establishing in vivo PDM model. The present study demonstrated that chemerin levels are decreased in the serum of patients with PDM and are negatively associated with the insulin resistance (IR) status. Chemerin levels also decreased during the development of PDM in C57BL/6 mice, together with increasing serum levels of interleukin‑1 and tumor necrosis factor‑α and decreasing mRNA expression levels of glucose transporter 2 (GLUT2) and pancreatic and duodenal homeobox 1 (PDX1). Treatment of PDM model mice with chemerin chemokine‑like receptor 1 (CMKLR1) agonist, chemerin‑9, elevated the serum levels of chemerin and mRNA expression levels of GLUT2 and PDX1, leading to the alleviation of glucose intolerance and IR in these animals. Together, the accumulated data indicated that chemerin may exert a protective function in PDM, perhaps by regulating perhaps by regulating GLUT2 and PDX1 expression, and that the restoration of the chemerin/CMKLR1 pathway may represent a novel therapeutic strategy for PDM.
View Figures
View References

Related Articles

Journal Cover

March 2020
Volume 21 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Tu, J., Yang, Y., Zhang, J., Lu, G., Ke, L., Tong, Z. ... Li, W. (2020). Regulatory effect of chemerin and therapeutic efficacy of chemerin‑9 in pancreatogenic diabetes mellitus. Molecular Medicine Reports, 21, 981-988. https://doi.org/10.3892/mmr.2020.10915
MLA
Tu, J., Yang, Y., Zhang, J., Lu, G., Ke, L., Tong, Z., Kasimu, M., Hu, D., Xu, Q., Li, W."Regulatory effect of chemerin and therapeutic efficacy of chemerin‑9 in pancreatogenic diabetes mellitus". Molecular Medicine Reports 21.3 (2020): 981-988.
Chicago
Tu, J., Yang, Y., Zhang, J., Lu, G., Ke, L., Tong, Z., Kasimu, M., Hu, D., Xu, Q., Li, W."Regulatory effect of chemerin and therapeutic efficacy of chemerin‑9 in pancreatogenic diabetes mellitus". Molecular Medicine Reports 21, no. 3 (2020): 981-988. https://doi.org/10.3892/mmr.2020.10915